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Abstract: In a research article published in BMC Medicine, Onakpoya and colleagues provide a historical review of
withdrawals of medications for safety reasons. However, withdrawn medications are only one part of the picture
about how regulatory agencies manage drug risks. Moreover, medications introduced before the increased pre-
marketing regulations and post-marketing monitoring systems instituted after the thalidomide tragedy have little
relevance when considering the present drug safety picture because the circumstances under which they were
introduced were completely different. To more fully understand drug safety management and regulatory agency
actions, withdrawals should be evaluated within the setting and timeframe in which the medications are approved,
which requires information about approvals and safety warnings. Studies are needed that provide a more
comprehensive current picture of the identification and evaluation of drug safety risks as well as how regulatory
agencies deal with them.
Please see related research article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0553-2
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Background
Humanity has long sought to ease its sufferings with the
use of medications, although few were effective and some
were dangerous [1]. At the beginning of the 20th century,
life expectancy was short, common infectious diseases had
a high fatality rate and surgery was risky. However, many
new medicines and vaccines were subsequently intro-
duced that offered significant improvements in the quan-
tity and quality of life. Some of the new medications had
serious adverse effects, but the overall improvement in
health up to 1960 generally overshadowed the risks.
The thalidomide disaster of 1961 [2] was a watershed
in the history of drug safety that led to a major change
in the understanding of and approach to drug safety. It
also led to the establishment of drug monitoring agen-
cies in many countries [3]. If an adverse drug reaction
(ADR) outweighs a medication’s benefits, these agencies
can require the product to be removed from the market.
Review of drugs withdrawn for safety reasons
In a recent article in BMC Medicine, Onakpoya et al. [4]
identified 462 medications discontinued for safety reasons
in one or more countries between 1953 and 2013 and cal-
culated three time periods for each product:
▪ Interval 1, years between launch year and year in
which an ADR related to the reason for withdrawal
was first reported;
▪ Interval 2, years between launch year and year of
withdrawal; and
▪ Interval 3, years between year in which an ADR
related to the reason for withdrawal was first reported
and year of withdrawal.
They concluded that intervals 1 and 2 have shortened
considerably over time, but there had been no consistent
reduction in interval 3. However, using their data, all
three intervals are seen to have decreased dramatically,
indicating a significant improvement in identifying and
acting upon major safety risks since the 1970s (Table 1).
Although reviews of withdrawals are interesting from a
historical perspective, medications introduced before the
increased pre-marketing regulations and post-marketing
monitoring systems instituted after thalidomide have little
relevance when considering the current safety picture be-
cause the circumstances under which they were intro-
duced were completely different. Over 40 % (187) of the
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medications in the review were introduced before 1961,
with 64 (14 %) before the Second World War and 23
(5 %) before 1900, so that they include some that were
brought into use when therapeutics consisted mainly of
bleeding, purging, sweating and vomiting [1]. For instance,
mercurous chloride (calomel) was prescribed by many
American physicians for a variety of illnesses from the late
1700s to well into the 19th century, although its dangers
were known before 1850 [5]. In addition, for 73 (16 %) of
the medications, an ADR related to the reason for with-
drawal was reported before 1961.
Understanding the context of drug withdrawals
A review of withdrawals provides only part of the picture
concerning medication safety and regulatory agency ac-
tions. The number of discontinued medications should
be placed within the context of the overall number ap-
proved in a specific setting and timeframe so that with-
drawal rates can be estimated. Information regarding
drug approvals is publicly available for many developed
countries and has been used to evaluate safety risks in
these jurisdictions [6–11]. Similar information may be
accessible for other countries, although language issues
may present a problem. Information from less developed
countries is likely to be more difficult to obtain. Neverthe-
less, pharmaceutical manufacturers can be approached for
information about where their products are approved and
pharmaceutical data companies may be able to provide in-
formation that would indicate where medications have
been approved.
Although Onakpoya and colleagues acknowledge that
the number of withdrawn medications represents ‘only a
small fraction of overall approvals’ [4], such details are
commonly ignored or overlooked by academics and poli-
ticians [12]. Therefore, it is critical that safety discon-
tinuation rates are evaluated. Where they have been
assessed in developed countries, the rate has remained
steady and low at around 2 % since the 1960s, with a de-
cline in recent years [6–11].
Among the withdrawn medications, 263 were ap-
proved after 1961, of which 40 % were discontinued in
only one country. Since approval information is absent,
it is unknown whether the medication was only ap-
proved in that country or whether it was approved in
multiple jurisdictions and only one country required
withdrawal. Each regulatory agency makes decisions re-
garding both marketing approval and drug safety issues
based on priorities in its particular jurisdiction. Faced
with reports of a serious ADR, some regulatory agencies
may compel the manufacturer to include a major warn-
ing in the product details, while others may require the
medication to be withdrawn. For example, rosiglitazone
was withdrawn in Europe, New Zealand and other coun-
tries, but Australia, Canada and the United States have
allowed it to remain on the market subject to stringent
restrictions that severely limit its use [13–15].
Onakpoya et al. also report a lack of association be-
tween intervals 1 and 3 [4]. Both intervals have de-
creased, but there is no reason for the time taken to
identify an ADR to be correlated with the period be-
tween first identification and discontinuation. Several
years may elapse before a serious ADR is recognized,
but it may take only days for the medication to be with-
drawn; on the other hand, an ADR may be reported
soon after a drug’s launch, but it may not be necessary
to withdraw the medication quickly. Factors that can in-
fluence the duration of interval 1 are the source of the
first ADR report (safety signals are more likely to be
identified from reports to manufacturers under current
pharmacovigilance practice, whereas case report publica-
tions were the main source of information in the past),
the timing of the marketing application and its approval
Table 1 Intervals 1, 2 and 3 by launch period
Launch period Interval Number of medications Median (years) Interquartile range (years)
Pre-1961 1 187 20 9–32
2 187 37 27–57
3 187 16 6–28
1961–1975 1 128a 8 3–15
2 131 17 10–22
3 128a 5 1–11
1976–1990 1 75 3 2–5
2 75 6 4–12
3 75 2 0–6
1991–2013 1 69 1 0–4
2 69 3 1–6
3 69 1 0–2
aYear of the first ADR report related to the reason for withdrawal was missing for three medications
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in each country (an ADR may be identified in the coun-
try where the medication is first submitted before other
countries have reviewed the product), the size of the
population (more rapid market penetration is likely to
occur in large jurisdictions which increases the likeli-
hood of early identification of an ADR), and physicians’
astuteness in recognizing an event as an ADR and their
willingness to report it. Since not all risks are equal, the
decision to withdraw a medication must take several
considerations into account, such as whether the prod-
uct has single or multiple indications, the availability of
other therapeutic options and the regulatory agency’s ap-
proach to risk management, all of which can affect the
extent of interval 3. The lack of information regarding
approvals and safety warnings in each country means
that a comprehensive picture of the relationship between
identification and management of a safety issue cannot
be constructed.
Conclusions
Medications introduced and discontinued more than
25–30 years ago have little relevance to the present
regulatory environment. Moreover, withdrawn medica-
tions are only one part of the picture of drug safety. In-
formation about approvals and safety warnings by
country is also required. Studies are needed that provide
a holistic current picture of the identification and evalu-
ation of drug safety risks as well as how regulatory agen-
cies deal with them.
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